The Promise And Pitfalls Of IO Exuberance And How To Rethink The Approach To Cancer Innovation
• By Dennis Chang, Keith Flaherty, and Uciane Scarlett
Immuno-oncology has produced some exciting successes, but the field has become intensely crowded. Enormous resources are being poured into duplicative work and shaky hypotheses—overshadowing other pursuits in cancer research while producing limited results. It is time to re-evaluate how the sector should be pursuing innovation in cancer and how it can be smarter in its use of resources—financial investment, talent, bandwidth, patients and data.
IO Has Become A Crowded Field With Many Players Attacking The Same Targets • Source: Shutterstock
Innovation in thinking and approaches holds the promise to drive innovation in cancer care. These three approaches will help the R&D sector pursue oncology innovation in a smarter, more effective way:
In oncology clinical development, every year brings new breakthroughs: drugs that can put previously intractable cancers into remission, or double...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
The Stanford professor-turned-CEO's 15-year journey demonstrates how scientific vision and focused leadership can revolutionize pharmaceutical supply chains.
A new AI-based platform is designed to condense months of clinical data analysis into minutes by translating plain language data queries into epidemiologically valid research requests.
Emerging research reveals that biological sex differences may significantly influence Alzheimer’s disease progression and treatment efficacy, underscoring the urgent need for sex-specific analysis in clinical trials and therapeutic development.
A new AI-based platform is designed to condense months of clinical data analysis into minutes by translating plain language data queries into epidemiologically valid research requests.
Emerging research reveals that biological sex differences may significantly influence Alzheimer’s disease progression and treatment efficacy, underscoring the urgent need for sex-specific analysis in clinical trials and therapeutic development.
